Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis
By Daniel H. Solomon, Elizabeth W. Karlson, E. Rimm, C. Cannuscio, L. Mandl, JoAnn E. Manson, MR Stampfer, G. Curhan. Circulation, 2003
1,293 citations recorded by the source corpus.
Subfields: Nephrology, Rehabilitation, Rheumatology
View Paper: https://www.semanticscholar.org/paper/cda9263cc6a9fe9d2c7dc538802cf43e3b38cedd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. (2005, result): “The CHD event rates (i.e., hospitalized MI and sudden death) in our study are within the range of values reported in various CHD surveillance studies, including one in our community (34,38,39), but are substantially higher than those reported among the participants of the Nurses’ Health Study (11).”
- Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts (2015, background): “5 to 2 fold increased risk compared to the general population [22, 23].”
- Cardiovascular death in rheumatoid arthritis: a population-based study. (2005, background): “The roles of diabetes and hypertension in the risk of cardiovascular morbidity and mortality in RA have been examined in a limited number of studies (11,20,21,52).”
- Angiogenesis in rheumatoid arthritis (2002, background): “48, respectively, when compared to women without RA [13].”
- EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis (2009, neutral): “8.”
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic (2004, methodology): “Finally, VIGOR used a population of rheumatoid arthritic patients, and it appears that rheumatoid arthritis is associated with a doubling in the risk of a myocardial infarction, with no increase in the chances of stroke (137).”
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register (2007, result): “When compared with published data on MI rates in the general population (35) and the risk conferred by RA (5,36), the observed rates in the DMARD cohort of 12.”